Unfortunately, for these reasons, conclusions cannot be made about the LRRC19 > IGFBP2 classifier as a predictor for Src sensitivity in patients with advanced pancreas cancer in this trial. This evidence concerns the gene IGFBP2 and pancreatic neoplasm.